VTE Risk Model in Children and a Novel Tri-specific T-cell-engager for MM

About this episode

This episode features an interview with Dr. Julie Jaffray and Dr. Ulrike Philippar discussing their recent research on venous thrombosis risk in children and a novel treatment for multiple myeloma.

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Julie Jaffray and Ulrike Philippar on their latest articles published in Blood . Dr. Jaffray discusses her CME article, " Multisite validation of a venous thrombosis risk model in critically ill children through the CHAT Consortium ", identifying patients with risks as high as 17% and taking research one step closer to the goal of personalized thromboprophylaxis for safe and effective care of high-risk children. Dr. Philippar discusses her article " Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models ", where the extensive in vitro and in vivo preclinical studies with cell lines and patient samples indicate strong potential for this agent to have efficacy against MM expressing either or both of these antigens.

People in this episode

Host: Dr. Laurie Sehn

Guests: Dr. Julie Jaffray, Dr. Ulrike Philippar

Topics covered

• venous thrombosis
• children
• personalized thromboprophylaxis
• multiple myeloma
• T-cell-engaging antibodies

Keywords

• venous thrombosis
• children
• thromboprophylaxis
• multiple myeloma
• T-cell-engaging antibody
• CME article
• preclinical studies

Mentioned in this episode

Organizations: CHAT Consortium

Books & works: Multisite validation of a venous thrombosis risk model in critically ill children through the CHAT Consortium, Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models

More episodes of Blood Podcast

• Future Directions in Relapsed and Refractory Large B-cell Lymphoma · June 11, 2026 · 25 min
• Review Series on Clonal Tracking in Hematopoiesis · June 4, 2026 · 30 min
• New Approaches: Marstacimab Therapy and HLH Biomarkers · May 28, 2026 · 18 min
• Review Series on Hemophagocytic Lymphohistiocytosis (HLH) · May 21, 2026 · 16 min
• IBD augmentation of CHIP and Platelet mTOR's impact on Cerebral Malaria · May 14, 2026 · 21 min
• Long-term efficacy and safety of betibeglogene autotemcel for β-thalassemia · May 7, 2026 · 13 min